Romano Brothers AND Company bought a new position in shares of Agilent Technologies, Inc. (NYSE:A – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 738 shares of the medical research company’s stock, valued at approximately $110,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. increased its holdings in Agilent Technologies by 1.9% during the 3rd quarter. BlackRock Inc. now owns 32,943,190 shares of the medical research company’s stock worth $4,004,242,000 after acquiring an additional 629,153 shares during the period. Vanguard Group Inc. increased its holdings in shares of Agilent Technologies by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 24,955,720 shares of the medical research company’s stock worth $3,033,368,000 after buying an additional 257,455 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Agilent Technologies by 1.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 16,652,764 shares of the medical research company’s stock worth $1,977,848,000 after buying an additional 223,279 shares during the last quarter. State Street Corp increased its holdings in shares of Agilent Technologies by 0.6% in the 3rd quarter. State Street Corp now owns 13,152,295 shares of the medical research company’s stock worth $1,598,661,000 after buying an additional 73,495 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Agilent Technologies by 10.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,478,670 shares of the medical research company’s stock worth $787,483,000 after buying an additional 627,517 shares during the last quarter.
Agilent Technologies Trading Up 0.6 %
Shares of A opened at $131.96 on Monday. The stock has a market capitalization of $39.02 billion, a P/E ratio of 29.79, a PEG ratio of 1.92 and a beta of 1.04. The company has a quick ratio of 1.53, a current ratio of 2.11 and a debt-to-equity ratio of 0.49. The firm has a fifty day simple moving average of $146.42 and a two-hundred day simple moving average of $143.19. Agilent Technologies, Inc. has a twelve month low of $112.52 and a twelve month high of $160.26.
Agilent Technologies declared that its Board of Directors has approved a stock buyback program on Monday, January 9th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 4.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.
Agilent Technologies Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 26th. Shareholders of record on Tuesday, April 4th will be issued a $0.225 dividend. The ex-dividend date is Monday, April 3rd. This represents a $0.90 annualized dividend and a yield of 0.68%. Agilent Technologies’s dividend payout ratio (DPR) is presently 20.32%.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. Credit Suisse Group increased their price target on shares of Agilent Technologies from $165.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, March 1st. SVB Leerink increased their price target on shares of Agilent Technologies from $160.00 to $170.00 and gave the stock an “outperform” rating in a report on Friday, January 6th. Wells Fargo & Company raised shares of Agilent Technologies from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $150.00 to $170.00 in a report on Tuesday, January 10th. Robert W. Baird upped their price objective on shares of Agilent Technologies from $170.00 to $174.00 and gave the company an “outperform” rating in a research note on Wednesday, March 1st. Finally, UBS Group upped their price objective on shares of Agilent Technologies from $152.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, December 20th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $163.31.
About Agilent Technologies
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
Read More
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 5 Best Dividend Capture Stocks
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
